Introduction
============

China has a high incidence of esophageal cancer, as this malignancy had the fourth highest mortality rate and the third highest incidence rate of all malignancies in 2015 ([@b1-ol-0-0-9747]). Esophageal squamous cell carcinoma (ESCC) is the major histological type of esophageal cancer in China, accounting for \>90% of all esophageal cancer cases ([@b2-ol-0-0-9747]). Although the application of combination treatment strategies that consist of surgery, chemotherapy and radiotherapy has improved the prognosis of ESCC, the 5-year overall survival (OS) rate remains low at 20--30% ([@b3-ol-0-0-9747]). Therefore, there is an urgent requirement to develop more effective therapeutic and prognostic strategies.

In previous years, notable therapeutic results have been achieved in advanced stages of cancer by blocking immune checkpoint molecules; of which programmed death-1 (PD)-1 and its ligand (PD-L1) have attracted substantial attention ([@b4-ol-0-0-9747]). Upon binding to PD-1, PD-L1 expressed on tumor cells and tumor-infiltrating lymphocytes (TILs), transduces inhibitory signals to regulate T-lymphocyte activation, tolerance and immune-mediated tissue damage, and promote the immune escape of tumor cells ([@b5-ol-0-0-9747]--[@b7-ol-0-0-9747]). Abnormal PD-L1 expression has been associated with the prognosis and therapeutic response in a number of malignancies, including esophageal cancer ([@b8-ol-0-0-9747]--[@b10-ol-0-0-9747]). Several studies revealed that PD-L1 positivity was significantly associated with disease progression, response to chemotherapy or radiotherapy, or disease control in ESCC ([@b8-ol-0-0-9747]--[@b10-ol-0-0-9747]). Notably, PD-L1 expression has been suggested to have positive ([@b8-ol-0-0-9747]) and negative prediction values in ESCC ([@b9-ol-0-0-9747]); therefore, the data on the prognostic value of PD-L1 expression in ESCC that is currently available remains limited and conflicting.

The present study aimed to determine the association between PD-L1 expression status and prognosis in an overall population of patients with ESCC and in subgroups of patients with ESCC who received chemotherapy or radiotherapy. The expression of PD-L1 in surgical ESCC specimens from 246 patients was examined, including those who underwent chemotherapy and/or radiotherapy following surgery. The association of PD-L1 expression with clinicopathological characteristics and survival was retrospectively analyzed with the aim of clarifying whether PD-L1 expression status was associated with a favorable or poor prognosis in patients with ESCC, including those undergoing different postoperative treatments.

Patients and methods
====================

### Patients

A total of 246 patients with resectable locally advanced ESCC, who underwent surgical treatment at the Zhejiang Cancer Hospital (Zhejiang, China) between January 2007 and December 2012, were included in the present study. All tissue specimens were obtained from the tissue bank of Zhejiang Cancer Hospital, and all patients provided written informed consent prior to surgery. The Institutional Review Board of Zhejiang Cancer Hospital provided ethical approval. Of the 246 patients, 222 (90.2%) were male and 24 (9.2%) were female. The median age of these patients at diagnosis was 58.0 years old (range, 37--80 years). The patients had not received preoperative chemotherapy, radiotherapy, targeted therapy or immune therapy. The surgical tumor specimens collected from these patients were used for immunohistochemical staining. Patient characteristics, including age, sex, history of smoking, alcohol drinking, Charlson comorbidity index (CCI) ([@b11-ol-0-0-9747]) and vessel invasion, and tumor characteristics \[size, differentiation, resection margin and TNM stage according to the 7th American Joint Committee on Cancer guidelines ([@b12-ol-0-0-9747])\] were recorded. Follow-ups were performed using clinical records every three months following patient discharge until mortality or the follow-up deadline (August 2016).

### Immunohistochemical staining

Immunohistochemical staining for PD-L1 was manually performed. ESCC specimens obtained from primary tumors were fixed with 10% formalin at 65°C, embedded in paraffin and cut into 4-µm sections. Tissues were immersed for 10 min in serial dilutions of xylene for de-waxing (dilution: 100, 90 and 80%), and then immersed in a graded alcohol series (dilution: 100, 90 and 80%) for 10 min to eliminate the xylene. Then, antigen retrieval was performed using PT-Link (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) subsequent to de-waxing at 95°C. Following immersion in 3% hydrogen peroxide to block endogenous peroxidase at room temperature for 30 min, the sections were incubated with an anti-PD-L1 rabbit monoclonal antibody (1:200; cat. no. 13684; E1L3N; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight, followed by incubation with a horseradish peroxidase-conjugated anti-rabbit secondary antibody (ready to use; cat. no. SM802; Envision FLEX HRP; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) for 30 min at room temperature. Subsequently, horseradish peroxidase activity was detected using 3,3′-diaminobenzidine at room temperature. The sections were counterstained using hematoxylin and examined under a light microscope (magnification, ×10 and ×40).

### Evaluation of immunohistochemical staining

Immunoreactivity for PD-L1 was evaluated semi-quantitatively using the H-score, which combines the staining intensity and the percentage of stained tumor cells ([@b13-ol-0-0-9747]). The staining intensity was graded on a four-point scale: 0, negative; 1, weak; 2, moderate and 3, strong. The percentage of stained tumor cells was scored between 0 and 100, increasing by 5% increments. Therefore, the final H-score values obtained ranged from 0 to 300. The H-scores were separated into low and high categories using the X-tile program (Olympus Corporation, Tokyo, Japan), with the mean H-score as the cutoff value ([@b14-ol-0-0-9747]). Two experienced pathologists independently calculated the percentage of stained tumor cells and the staining intensity and discussed to reach a consensus in cases where there were disagreements.

### Statistical analysis

All statistical analyses were performed using IBM SPSS software (version 22; IBM Corp., Armonk, NY, USA). Associations between clinicopathological variables and PD-L1 expression were analyzed using a Pearson\'s χ^2^ test. The Kaplan-Meier method and log rank test were used to calculate the rate of OS and to compare differences between the survival curves. Cox\'s proportional hazard regression model was utilized to compare categorical variables using backward elimination with a stay level of 0.10. Logistic regression was performed to investigate the association between PD-L1 expression status and clinicopathological factors using a backward regression procedure that included variables where P\<0.1 in the univariate analysis. All P-values were two-tailed, and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of PD-L1 in ESCC tissues

PD-L1 was expressed on the membrane and in the cytoplasm, and PD-L1 expression exhibited heterogeneity in the ESCC specimens ([Fig. 1](#f1-ol-0-0-9747){ref-type="fig"}). The mean H-score for PD-L1 expression in the patient population was 16 (range, 0--240). According to a cut-off value of 15 obtained using X-tile software analysis, 60 (24.4%, 60/246) patients were considered positive for PD-L1.

### Association between PD-L1 expression status and clinicopathological factors in ESCC patients

The clinicopathological characteristics of patients are summarized in [Table I](#tI-ol-0-0-9747){ref-type="table"}. Among these patients, 222 (90.2%, 222/246) were male and 24 (9.8%, 24/246) were female. The median age of these patients was 58.0 years old (range, 37--80 years old) at diagnosis, and the median OS time was 53.0 months \[95% confidence interval (CI), 41.4--64.6 months\]. The χ^2^ test revealed a significant association between positive PD-L1 expression and tumor node metastasis (TNM) stage (P=0.022). However, there was no association between positive PD-L1 expression and factors, including age, sex, CCI, smoking history, alcohol drinking, vessel invasion, tumor differentiation, tumor location, T stage and N stage. Multivariate logistic regression analysis also indicated that PD-L1 expression was significantly associated with TNM stage in patients with ESCC (P=0.009; [Table II](#tII-ol-0-0-9747){ref-type="table"}).

### Association between PD-L1 expression and survival in patients with ESCC

Next, the survival outcomes of patients with ESCC based on PD-L1 expression status were assessed. During the follow-up period, 139 (56.5%, 139/246) patients succumbed to mortality. The median OS time of the 246 patients was 53.0 months (95% CI, 41.4--64.6 months). For patients with positive PD-L1 expression, the OS time was 52.4 months (95% CI, 30.3--74.5 months), whereas for patients with negative PD-L1 expression, the OS time was 56.4 months (95% CI, 43.0--69.8 months). However, the difference between the OS time of patients who were positive and those who were negative for PD-L1 was not statistically significant, as presented by the Kaplan-Meier analysis (P=0.466; [Fig. 2](#f2-ol-0-0-9747){ref-type="fig"}).

The survival outcomes in patients receiving different treatments were also assessed ([Fig. 3](#f3-ol-0-0-9747){ref-type="fig"}). Among the 246 patients with ESCC, 106 patients received surgical resection alone, 26 patients received surgery in addition to adjuvant chemotherapy, 36 patients received surgery with adjuvant radiotherapy and 78 patients underwent surgery in addition to adjuvant chemoradiotherapy. In the surgery-alone group, there was no significant difference in OS time between PD-L1-positive and -negative patients \[41.5 months (95% CI, 15.7--67.4 months) vs. 58.9 months (95% CI, 29.2--88.7 months), respectively; P=0.706; [Fig. 3A](#f3-ol-0-0-9747){ref-type="fig"}\]. In the surgery with adjuvant chemotherapy subgroup, there was also no statistical difference in OS time between PD-L1-positive and -negative patients (21.8 vs. 41.0 months, respectively; P=0.765; [Fig. 3B](#f3-ol-0-0-9747){ref-type="fig"}). Notably, in the surgery with adjuvant radiotherapy subgroup, there was a statistical significant difference between patients with positive and negative PD-L1 expression \[84.4 months (95% CI, 55.2--113.6 months) vs. 36.0 months (95% CI, 18.9--53.1 months), respectively; P=0.046; [Fig. 3C](#f3-ol-0-0-9747){ref-type="fig"}\]. Furthermore, in the surgery with adjuvant chemoradiotherapy subgroup, there was a tendency for patients with ESCC that had positive PD-L1 expression to have a shorter OS compared with patients with negative PD-L1 expression \[38.5 months (95% CI, 17.8--59.2 months) vs. 69.1 months (95% CI, 25.2--113.0)\]; however, this difference was not significant (P=0.061; [Fig. 3D](#f3-ol-0-0-9747){ref-type="fig"}).

### Univariate and multivariate analyses of factors affecting survival in patients with ESCC

As presented in [Table III](#tIII-ol-0-0-9747){ref-type="table"}, univariate Cox regression analysis revealed that lymph node metastasis and TNM stage were significant prognostic factors for OS in patients with ESCC \[hazard ratio (HR)=1.61, 95% CI, 1.15--2.26, P=0.005; HR, 1.62, 95% CI, 1.15--2.29, P=0.006, respectively\]. Vessel invasion showed a tendency to be a prognostic factor, but the P-value was not statistically significant (HR=1.47; 95% CI, 0.99--2.17; P=0.058). Unexpectedly, PD-L1 expression status was not a significant prognostic factor for OS in patients with ESCC (HR, 1.15, 95% CI, 0.79--1.68, P=0.467). Multivariate Cox regression hazards analysis revealed that lymph node metastasis (P=0.002), vessel invasion (P=0.011) and smoking history (P=0.049) were independent prognostic factors in patients with ESCC. Patients with advanced N stage, vessel invasion or smoking history had poorer survival than patients with early N stage, non-vessel invasion of non-smoking history ([Table III](#tIII-ol-0-0-9747){ref-type="table"}). Similarly, multivariate analysis indicated that PD-L1 expression status was not a significant independent prognostic factor (HR, 1.05; 95% CI, 0.70--1.59; P=0.804).

Discussion
==========

The present study investigated the expression of PD-L1 and its association with the clinicopathological factors and clinical outcomes of different treatments in patients with resectable locally advanced ESCC. It was detected that PD-L1 expression was significantly associated with TNM stage in ESCC. High PD-L1 expression is positively associated with advanced TNM stage. In addition, it was revealed that PD-L1 expression was a potential predictor of a favorable response to radiotherapy in patients with ESCC, although median OS time did not differ significantly between patients with positive and negative PD-L1 expression in the overall population.

Although one previous study did not reveal any significant associations between PD-L1 expression and clinicopathological factors in 177 patients with ESCC ([@b15-ol-0-0-9747]), other studies obtained different results. A study conducted by Chen *et al* ([@b16-ol-0-0-9747]) on ESCC revealed that PD-L1 expression associated with factors, including upper esophageal location, well-differentiated tumor type, an absence of lymph node metastasis and an early stage of disease suggesting that PD-L1 expression is an indicator of less aggressive tumor types. By contrast, a number of other studies have indicated that basal high PD-L1 expression is positively associated with advanced T stage, lymph node metastasis and loco-regional failure in ESCC ([@b17-ol-0-0-9747]--[@b19-ol-0-0-9747]). In the present study, it was revealed that patients with ESCC with an advanced TNM stage had a significant association with positive PD-L1 expression, and these results suggest that positive PD-L1 expression may be associated with malignant biological behavior in ESCC. However, whether PD-L1 expression results in an advanced TNM stage or whether an advanced TNM stage promotes PD-L1 expression remains unknown. Further studies are required to investigate this.

The present study also revealed that patients with positive and negative PD-L1 expression had similar median OS time (52.4 months vs. 56.4 months, P=0.466), which is inconsistent with a majority of previous studies. For instance, three meta-analyses indicated that PD-L1 expression was associated with a poorer OS time in esophageal cancer ([@b20-ol-0-0-9747]--[@b22-ol-0-0-9747]). However, one study revealed that a high PD-L1 expression predicted a favorable prognosis in patients with ESCC ([@b8-ol-0-0-9747]). The discrepancies among different studies in terms of the association of PD-L1 expression status with clinicopathological factors and survival in ESCC may be due to a combination of several reasons as follows: Different sensitivities of antibodies used; different cut-off values for positive PD-L1 staining; non-uniform PD-L1 expression (as detected in [Fig. 1E and F](#f1-ol-0-0-9747){ref-type="fig"} in the present study) and different sampling timing and location ([@b23-ol-0-0-9747]). In the present study, no association was detected between PD-L1 expression and prognosis in ESC. Future studies should carefully address these issues in order to standardize the immunohistochemical staining procedure and interpretation of immunohistochemical results, enabling the comparison of results obtained from different studies.

Notably, the results of the present study indicated that in patients treated with adjuvant radiotherapy, the prognosis was significantly improved in patients with positive PD-L1 expression compared with those with negative PD-L1 expression (median OS time, 84.4 months vs. 36.0 months; P=0.046). In patients treated with adjuvant chemotherapy, median OS was poorer in PD-L1-positive patients compared with PD-L1-negative patients, although there was no significant statistical difference (21.8 months vs. 41.0 months, P=0.765). In agreement with this finding, a number of previous studies have indicated that there is an association between PD-L1 expression and the outcomes of different types of clinical management. In a study of 177 Japanese patients with ESCC who underwent an esophagectomy without preoperative therapy, PD-L1 expression was significantly associated with an improved prognosis in patients who underwent surgery alone, but not in patients treated with surgery plus postoperative adjuvant chemotherapy ([@b15-ol-0-0-9747]). Another study of 180 Japanese patients with ESCC who were treated by radical resection with or without preoperative neoadjuvant chemotherapy revealed that PD-L1 expression correlated with a poorer OS time in patients treated with preoperative neoadjuvant chemotherapy, but not in those without preoperative neoadjuvant chemotherapy ([@b24-ol-0-0-9747]). Theoretically, ESCC is moderately sensitive to chemotherapy, but the role of postoperative chemotherapy against ESCC has been debated. The National Comprehensive Cancer Network only recommends postoperative chemotherapy for patients with ESCC with R1 (cancer cells present by microscopy at the resection) or R2 resections (tumor tissue present by naked eyes at the resection margin) ([@b25-ol-0-0-9747]). The present study revealed that PD-L1-positive patients with ESCC do not benefit from postoperative adjuvant chemotherapy, which indicates that chemotherapy not only has a direct cytotoxic effect on tumor cells, but may also affect the tumor immune system ([@b15-ol-0-0-9747]).

Radiotherapy is one of the main types of treatment for ESCC ([@b25-ol-0-0-9747]). Radiation increases the leakage of tumor antigens by killing tumor cells and promotes the activation of tumor-specific T cells by increasing the ability of antigen-presenting cells to display antigens on their surface ([@b26-ol-0-0-9747]). Previous studies have documented the synergism between several types of immunotherapy and radiotherapy ([@b27-ol-0-0-9747]). Previous preclinical studies have revealed that PD-L1 expression may be upregulated in tumor cells by radiation therapy ([@b28-ol-0-0-9747],[@b29-ol-0-0-9747]). In addition, anti-PD-L1 therapy combined with radiotherapy improves survival compared with radiotherapy alone in mice ([@b30-ol-0-0-9747]).

PD-L1 expression on tumor cells is generally considered to be one of the mechanisms for immune evasion via downregulating the function of TILs (CD8^+^ T-lymphocytes and CD4^+^ T-lymphocytes) or activating the epidermal growth factor receptor signaling pathway ([@b31-ol-0-0-9747]--[@b33-ol-0-0-9747]). However, in the present study, positive PD-L1 expression was associated with a favorable survival in patients who underwent radiotherapy. It was hypothesized that patients with PD-L1 expression had highly immunogenic tumors prior to radiation therapy, which indicates a strong adaptive immune response. In patients with PD-L1 expression, there was an increased infiltration of other subpopulations of TILs, which has been reported to be a strong predictor of good prognosis for patients with ESCC ([@b34-ol-0-0-9747]). A number of studies reported that high PD-L1 expression on tumor cells was associated with increased intraepithelial CD3^+^ T-lymphocytes, and both factors were associated with a favorable prognosis in ESCC ([@b8-ol-0-0-9747],[@b35-ol-0-0-9747]).

Autophagy is an evolutionarily conserved process for the clearance of damaged or superfluous intracellular products via the lysosomal-mediated pathway ([@b36-ol-0-0-9747]). Autophagy is associated with a decrease in radiosensitivity. Autophagy inhibitor combined with radiotherapy resulted in enhanced cytotoxicity of radiotherapy in ESCC cells by decreasing the expression of autophagy-associated gene Beclin1 and arresting the cell cycle at the G2/M phase ([@b37-ol-0-0-9747],[@b38-ol-0-0-9747]). Tumor-intrinsic PD-L1 signals promote mammalian target of rapamycin (MTORC)1 and inhibit MTORC2, therefore inhibiting autophagy and enhancing the sensitivity to growth suppression by autophagy inhibitors ([@b39-ol-0-0-9747]). However, a number of studies reported that PD-L1 promoted immune evasion via activation of the protein kinase B/mTOR oncogenic pathway ([@b40-ol-0-0-9747],[@b41-ol-0-0-9747]). Other studies reported that PD-L1 expression was associated with resistance to anticancer therapies, including radiotherapy and chemotherapy ([@b19-ol-0-0-9747],[@b42-ol-0-0-9747]).

The mechanisms responsible for the survival benefit of PD-L1 in patients with ESCC receiving radiotherapy remain to be further investigated. The present study was based on surgical samples obtained from patients with ESCC who did not undergo preoperative chemotherapy, radiotherapy or immunotherapy, suggesting that basal PD-L1 expression status may serve as a potential predictive factor of the effects of adjuvant radiotherapy. Additional research should be performed to investigate the potential molecular mechanism of these associations for ESCC. Studies with larger sample sizes are required to clarify this issue.

The present study was subjected to certain limitations. First, although the present study had a larger sample size compared with other studies ([@b16-ol-0-0-9747],[@b43-ol-0-0-9747]), there was still bias due to its retrospective design. Secondly, only 24.4% of these patients were regarded as PD-L1-positive, while a meta-analysis demonstrated that nearly 50% of patients with gastrointestinal cancer were positive for PD-L1 expression, regardless of the evaluation method used ([@b20-ol-0-0-9747]). The standard used for the positive expression of PD-L1 in the present study was inconsistent with several previous studies ([@b20-ol-0-0-9747]--[@b22-ol-0-0-9747]), and there was no unified standard for the positive expression of PD-L1. Whether the threshold selected to determine PD-L1 expression was positive or negative may be arbitrary. In the present study, PD-L1 expression in a number of ESCC tumor tissues appeared to be heterogeneous ([Fig. 1E and F](#f1-ol-0-0-9747){ref-type="fig"}). Consistent with this observation, previous studies have revealed that PD-L1 expression was heterogeneous in other malignant tumors ([@b44-ol-0-0-9747]--[@b46-ol-0-0-9747]). Therefore, heterogeneous expression may be another reason why the PD-L1 positive rate in the present study was lower compared with those in other studies ([@b20-ol-0-0-9747]--[@b22-ol-0-0-9747]). Finally, as no standardized PD-L1 immunohistochemistry assay is currently available, caution should be taken in the interpretation of these results.

In conclusion, the present study demonstrates, to the best of our knowledge, for the first time that high PD-L1 expression in associated with a favorable prognosis in patients with ESCC undergoing postoperative adjuvant radiotherapy. However, this association was not consistent in the overall ESCC population. Therefore, patients with positive PD-L1 expression may benefit from postoperative adjuvant radiotherapy. However, further studies are required in order to confirm these results.

The present study was presented as a conference abstract (Oral no. 117) on 2--5 September, 2017 at the 14th World Conference Global Perspectives in Esophageal Diseases in Geneva, Switzerland.
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![Immunohistochemical staining of PD-L1 in esophageal squamous cell carcinoma tissues. Images obtained from three different patients. Positive expression of PD-L1 \[magnification, (A) ×20 and (B) ×40\]. Negative expression of PD-L1 \[magnification, (C) ×20 and (D) ×40\]. Heterogeneity of PD-L1 expression \[magnification, (E) ×10 and (F) ×20\]. Image B, D and F were magnified from image A, C and E. PD-L1, programmed death-ligand 1.](ol-17-02-1626-g00){#f1-ol-0-0-9747}

![Kaplan-Meier curve of the overall survival time of patients with esophageal squamous cell carcinoma based on PD-L1 expression status. PD-L1, programmed death-ligand 1.](ol-17-02-1626-g01){#f2-ol-0-0-9747}

![Subgroup analysis of overall survival time in esophageal squamous cell carcinoma patients based on PD-L1 expression. Patients undergoing (A) surgery alone; (B) a combination of surgery and adjuvant chemotherapy; (C) combination of surgery and adjuvant radiotherapy or (D) surgery and adjuvant chemoradiotherapy. PD-L1, programmed death-ligand 1.](ol-17-02-1626-g02){#f3-ol-0-0-9747}

###### 

Association between PD-L1 expression and clinicopathological factors in patients with esophageal squamous cell carcinoma.

                                                           PD-L1         
  -------------------------------------------------------- ------- ----- -------
  Age, years                                                             0.312
    \<65                                                   48      159   
    ≥65                                                    12      27    
  Sex, n                                                                 0.942
    Female                                                 6       18    
    Male                                                   54      168   
  CCI                                                                    0.600
    Low                                                    8       19    
    Moderate                                               51      160   
    High                                                   1       7     
  Vessel invasion                                                        0.137
    Yes                                                    13      59    
    No                                                     47      127   
  Differentiation                                                        0.542
    Well                                                   17      67    
    Moderate                                               36      101   
    Poor                                                   7       18    
  Tumor location                                                         0.209
    Upper                                                  21      77    
    Middle                                                 39      103   
    Lower                                                  0       6     
  T stage                                                                0.109
    1--2                                                   10      136   
    3--4                                                   50      50    
  N stage                                                                0.213
    0--1                                                   33      119   
    2--3                                                   27      67    
  TMN stage^[a](#tfn1-ol-0-0-9747){ref-type="table-fn"}^                 0.022
    II                                                     27      132   
    III                                                    33      54    
  Smoking history                                                        0.837
    Yes                                                    47      148   
    No                                                     13      38    
  Alcohol consumption                                                    0.892
    Yes                                                    46      141   
    No                                                     14      45    

According to the 7th American Joint Committee on Cancer guidelines. CCI, Charlson comorbidity index; TNM, tumor-node metastasis; T stage, tumor stage; N stage, node stage; PD-L1, programmed death-ligand 1.

###### 

Multivariate logistic regression analysis of risk factors for programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.

  Variable              OR     95% CI       P-value
  --------------------- ------ ------------ ---------
  Sex                   1.01   0.34--3.01   0.993
  Age                   1.33   0.61--2.91   0.473
  Smoking history       1.25   0.60--2.61   0.553
  Alcohol consumption   1.02   0.45--2.33   0.953
  Vessel invasion       2.04   1.00--4.17   0.051
  T stage               1.33   0.59--3.01   0.494
  N stage               1.82   0.57--5.82   0.311
  TNM stage             2.30   1.23--4.29   0.009

OR, odds ratio; CI, confidence interval; TNM, tumor-node metastasis; T stage, tumor stage; N stage, node stage.

###### 

Univariate and multivariate Cox regression analyses of factors affecting the overall survival time of patients with esophageal squamous cell carcinoma (n=246).

  A, Univariate analysis                                                           
  -------------------------------------------------------- -------- -------------- -------------
  PD-L1                                                                            
    Positive vs. negative                                  1.152    0.787--1.684   0.467
  Sex                                                                              
    Male vs. female                                        1.106    0.624--1.961   0.730
  Age (years)                                                                      
    ≥65 vs. \<65                                           1.080    0.700--1.665   0.729
  Smoking history                                                                  
    Yes vs. no                                             1.388    0.894--2.156   0.144
  Alcohol drinking                                                                 
    Yes vs. no                                             1.100    0.746--1.621   0.631
  CCI                                                                              
    Low vs. moderate vs. high                              1.176    0.741--1.866   0.491
  Vessel invasion                                                                  
    Yes vs. no                                             1.466    0.987--2.174   0.058
  Tumor differentiation                                                            
    Well vs. moderate vs. poor                             1.055    0.814--1.366   0.688
  Tumor location                                                                   
    Lower vs. middle vs. upper                             1.242    0.907--1.704   0.177
  T stage                                                                          
    T1-2 vs. T3-4                                          1.100    0.741--1.631   0.637
  N stage                                                                          
    N0-1 vs. N2-3                                          1.613    1.152--2.257   0.005
  TNM stage^[a](#tfn3-ol-0-0-9747){ref-type="table-fn"}^                           
    II vs. III                                             1.623    1.151--2.288   0.006
  Chemotherapy                                                                     
    Yes vs. no                                             1.038    0.741--1.456   0.827
  Radiotherapy                                                                     
    Yes vs. no                                             1.168    0.838--1.631   0.359
                                                                                   
  **B, Multivariate analysis**                                                     
                                                                                   
  **Variable**                                             **HR**   **95% CI**     **P-value**
                                                                                   
  PD-L1                                                                            
    Positive vs. negative                                  1.053    0.698--1.589   0.804
  Sex                                                                              
    Male vs. female                                        1.051    0.545--2.028   0.882
  Age, years                                                                       
    ≥65 vs. \<65                                           1.049    0.652--1.690   0.843
  Smoking history                                                                  
    Yes vs. no                                             1.658    1.002--2.740   0.049
  Alcohol drinking                                                                 
    Yes vs. no                                             1.454    0.935--2.262   0.097
  CCI                                                                              
    Low vs. moderate vs. high                              1.053    0.664--1.669   0.826
  Vessel invasion                                                                  
    Yes vs. no                                             1.685    1.128--2.518   0.011
  Tumor differentiation                                                            
    Well vs. moderate vs. poor                             1.104    0.838--1.456   0.483
  Tumor location                                                                   
    Lower vs. middle vs. upper                             1.248    0.908--1.718   0.172
  T stage                                                                          
    T1-2 vs. T3-4                                          1.068    0.665--1.717   0.785
  N stage                                                                          
    N0-1 vs. N2-3                                          1.709    1.215--2.404   0.002
  TNM stage^[a](#tfn3-ol-0-0-9747){ref-type="table-fn"}^                           
    II vs. III                                             1.350    0.777--2.347   0.287
  Chemotherapy                                                                     
    Yes vs. no                                             1.092    0.740--1.611   0.659
  Radiotherapy                                                                     
    Yes vs. no                                             1.183    0.838--1.672   0.339

TNM staging was performed according to the 7th American Joint Committee on Cancer guidelines. CCI, Charlson comorbidity index; HR, hazard ratio; CI, confidence interval; PD-L1, programmed death-ligand 1; TNM, tumor-node-metastasis; T stage, tumor stage; N stage, node stage.

[^1]: Contributed equally
